Stock-Based Compensation: The estimated market value of stock options, warrants and other stock-based compensation given to employees and/or vendors.
Benitec Biopharma Limited (BNTC) had Stock-Based Compensation of $20.15M for the most recently reported fiscal quarter, ending 2026-03-31.
| Income Statement Financials | |
-- |
|
$-11.94M |
|
-- |
|
-- |
|
$13.58M |
|
$-13.58M |
|
$1.65M |
|
$-11.94M |
|
$-11.94M |
|
$-11.94M |
|
$-11.94M |
|
$-11.94M |
|
$-11.94M |
|
$-13.58M |
|
$-13.57M |
|
49.39M |
|
49.39M |
|
$-0.24 |
|
$-0.24 |
|
| Balance Sheet Financials | |
$186.02M |
|
$0.12M |
|
$0.98M |
|
$187.00M |
|
$3.27M |
|
$0.39M |
|
$0.39M |
|
$3.67M |
|
$183.33M |
|
$183.33M |
|
$183.33M |
|
34.35M |
|
| Cash Flow Statement Financials | |
$-11.58M |
|
$-0.03M |
|
$98.74M |
|
$97.86M |
|
$184.88M |
|
$87.02M |
|
|
Stock-Based Compensation |
$20.15M |
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
56.82 |
|
-- |
|
-- |
|
0.00 |
|
0.00 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-11.61M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-6.51% |
|
-6.51% |
|
-6.38% |
|
-6.50% |
|
$5.34 |
|
$-0.23 |
|
$-0.23 |
|